About this Webinar:
Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors.
Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies.
Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient.
Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design of precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points.
IHC methods are therefore insufficient for generating a comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. However, the quantitative assessment of the accuracy and precision of such multiplex panels is key for their widespread use in clinical samples.
You’ll learn about:
- The development and validation process of a high throughput, high-plex mIF assay to derive meaningful biological insights
- How advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context
- How whole slide image analysis of the tumor microenvironment can provide insight into specific cancer types
About the presenter(s):
Lorcan Sherry, PhD. — Chief Scientific Officer at OracleBio
As co-founder and Chief Scientific Officer at OracleBio, Lorcan has helped establish the company as a market leader within its field, supporting the digital pathology programmes of major Pharma and Biotech companies around the globe.
Day to day, Lorcan oversees a team of image analysis scientists and pathologists responsible for the execution of Client image analysis R&D studies, while further driving the adoption of innovative techniques and processes to improve the quality and efficiency of our services.
Angela Vasaturo, PhD. — Associate Director Scientific Affairs at Ultivue
Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre.
She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.
Discover more Webinars:
About this Webinar: This session, 'Using Artificial Intelligence (AI) to support Quantitative Digital Pathology in R&D', was live on Wednesday 17th November 2021. You can re-watch the full webinar including the Q&A above. Presented by OracleBio's Chief...
Good clinical practice (GCP) is an internationally recognised ethical and scientific standard for designing, recording and reporting trials that involve the participation of human subjects. For quantitative image analysis data to be included in a data package...
OracleBio is a global leader in quantitative digital pathology services to Pharma and Biotech clients worldwide. Leveraging industry-leading image analysis software platforms, the company delivers robust data packages to support clinical trials and translational...
Find out more about our Multiplex IF Analysis
OracleBio's Quantitative Digital Pathology Services
Stay up to date with OracleBio
Sign up to our mailing list to stay informed about news, webinars, events and more